Lowest Price Guaranteed From USD 4,799
Published
March 2023
Pages
270
View Count
9264
Example Insights
Please refer below for insights
Report Description
The aseptic fill finish manufacturing market is estimated to be worth USD 5.4 billion in 2023 and is expected to grow at compounded annual growth rate (CAGR) of 9%, during the forecast period. Aseptic fill finish refers to accurate and sterile fill finish / sealing of drug products into packaging containers, such as vials, prefilled syringes, ampoules and cartridges. These aseptic conditions during fill-finish operations are not only essential for ensuring end-user’s safety, but also maintaining pharmacological efficacy and product quality. It is worth noting that aseptic fill finish manufacturing requires skilled personnel, specialized automated equipment, clean room setup and continuous supervision to maintain the sterility and safety of the final drug product. However, given the high cost of specialized equipment and affiliated expertise required for fill-finish operations, it is difficult for a drug developer with limited finances and capacity constraints to meet the needs of their clientele. As a result, various stakeholders are outsourcing their fill finish manufacturing related needs to contract service providers, in order to ensure the development of quality drug products. In fact, a number of companies are involved in offering services for aseptic fill finish of a wide range of biologics and small molecules. Additionally, there is a need for expanding the capacity to meet the anticipated demand for such operations. For this purpose, service providers have inked several agreements over the last few years. Driven by the consistent initiatives being undertaken by companies in this industry, the aseptic fill finish manufacturing market is anticipated to grow at a steady pace, over the forecast period.
![]() |
![]() |
![]() |
The Aseptic Fill Finish Manufacturing Market by Type of Molecule (Small Molecules and Biologics), Type of Packaging Container Offered (Ampoules, Cartridges, Prefilled Syringe and Vials), Type of Drug Product (Antibodies, Cell Therapies, Gene Therapies, Oligonucleotides, Recombinant Proteins, Vaccines and Other Products), Scale of Operation (Preclinical / Clinical and Commercial), Company Size (Large, Mid-sized and Small), Target Therapeutic Area (Autoimmune Disorders, Cardiovascular Disorders, Infectious Diseases Oncological Disorders, and Other Disorders) and Geographical Regions (North America, Europe, Asia Pacific, Middle East and North Africa and Latin America): Industry Trends and Global Forecasts, 2023-2035 report features an extensive study of the current market landscape, market size and future opportunity for the aseptic fill finish service providers. Some of the key takeaways from the market report are mentioned below.
Aseptic fill finish is a critical step in the production of drugs, as it involves the aseptic fill and finish of therapeutic products into containers. In fact, even a minute error during the fill finish manufacturing process can lead to microbial contamination, posing a considerable risk to the patient’s health. Therefore, aseptic fill finish operations need to be performed under controlled environmental conditions, in order to minimize the exposure of drug product to factors that could negatively impact its stability and efficacy. This, in turn, helps in extending the shelf life of a drug product. It is also worth mentioning that, in recent years, many players are carrying out fill-finish operations using automated equipment, without any manual intervention. This practice is believed to enhance the production efficiency, minimize downtime, reduce waste production, as well as increase the overall productivity. ,
The growing demand for pharmaceutical and biopharmaceutical drug products has created a need for higher capacity for production of therapies and their corresponding sterile fill finish operations. However, extensive capital investment and complex infrastructure is necessary for carrying out in-house fill&finish of biologics and small molecules. In addition, mishandling of drug product during the fill-finish process can lead to microbial contamination, which can subsequently result in the loss of drug product, production delays and most importantly, pose a risk to the patient’s health. These aforementioned challenges have prompted pharmaceutical drug developers to outsource their sterile fill finish operations to service providers, which have the required fill finish facility and specialized equipment to ensure the quality of end products. With the growing demand for biologics and the advent of new generation of complex biologics and ATMPs, the aseptic fill finish manufacturing market for the contract manufacturers will continue to witness healthy market growth over the forecast period.
At present, the rising demand for outsourcing of aseptic fill finish services is driven by multiple factors, such as growing pipeline of drug products, stringent regulatory requirements, in-house capacity constraints, technological advancements and increased awareness related to the benefits of aseptic fill finish services.
The current market landscape features the presence of over 235 aseptic fill finish service providers, spread across the globe. Overall, the market seems to be well-fragmented, featuring the presence of large, mid-sized and small companies, which have the required expertise to offer aseptic fill finish services across different types of packaging containers such as pharmaceutical vials and prefilled syringe. Additionally, various recent developments in this segment of the pharmaceutical industry indicate that service providers are actively upgrading their sterile fill finish capabilities and infrastructure to accommodate the current and anticipated demand for aseptic fill finish services.
Driven by the growing pipeline of pharmaceutical and biopharmaceutical drug products, as well as the rising demand for contract manufacturing in this sector, the aseptic fill finish manufacturing market is anticipated to grow at a CAGR of 9%, during the forecast period. Specifically, in terms of type of packaging container, the highest market share is anticipated to be captured by vials and prefilled syringe. In addition, at present, a major proportion of the market is represented by players based in North America and Europe. However, over the forecast period, Asia Pacific market is anticipated to grow at a higher CAGR.
Examples of key companies engaged in offering sterile fill finish services for biologics and small molecules include (which have been captured in this report) Aenova, AbbVie Contract Manufacturing, APL, Asymchem, BioPharma Solutions, BioReliance, Boehringer Ingelheim BioXcellence, Catalent Biologics, Charles River Laboratories, CordenPharma, Delpharm, Fareva, Fresenius Kabi, Glaxo SmithKline, Hetero Drugs, Intas Pharmaceuticals, Lonza, Pierre Fabre, Patheon, Pfizer CentreOne, Plastikon Healthcare, PiSA Farmaceutica, Recipharm, Sharp Services, Wacker Biotech, Syngene, Takara Bio, WuXi Biologics, Siegfried and Wockhardt. This market report includes an easily searchable excel database of all the aseptic fill finish CMO worldwide.
Several recent developments have taken place in the field of aseptic fill finish market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
![]() |
![]() |
![]() |
The market report presents an in-depth analysis of the various firms / organizations that are engaged in this industry, across different segments, as defined in the below table:
Key Report Attributes | Details | |
Base Year |
2022 |
|
Forecast Period | 2023-2035 | |
Historical Period |
2018-2022 |
|
Market Size 2023 | $5.4 billion | |
CAGR | ~9% | |
Type of Molecules | Small Molecules, Biologics | |
Type of Packaging Containers Offered | Vials, Syringes, Ampoules, Cartridges | |
Type of Drug Products | Vaccine, Recombinant Proteins, Antibodies, Oligonucleotides, Gene Therapies, Cell Therapies, Other Products | |
Target Therapeutic Area | Autoimmune Disorders, Cardiovascular Disorders , Infectious Disorders, Oncological Disorders , Other Disorders | |
Scale of Operation | Preclinical / Clinical, Commercial | |
Company Size | Large, Mid-sized, Small | |
Geography | North America, Europe, Asia Pacific, Middle East and North Africa, Latin America | |
Key Companies Profiled |
AbbVie Contract Manufacturing, Asymchem , Aenova , APL, BioPharma Solutions, BioReliance, Boehringer Ingelheim BioXcellence, Catalent Biologics, Charles River Laboratories , CordenPharma, Delpharm, Fareva, Fresenius Kabi, Glaxo SmithKline, Hetero Drugs, Intas Pharmaceuticals, Lonza, Pierre Fabre, Pfizer CentreOne, Plastikon Healthcare, Patheon, PiSA Farmaceutica, Recipharm, Wacker Biotech, Syngene, Sharp Services, Siegfried, Takara Bio, WuXi Biologics, Wockhardt (Full list of 235+ companies captured in the market landscape analysis of the report) |
|
Customization Scope | 15% Free Customization Option | |
PowerPoint Presentation (Complimentary) | Available | |
Excel Data Packs (Complimentary) | Market Landscape Analysis, Developers Landscape Analysis, Partnership and Collaboration Analysis, Market Forecast and Opportunity Analysis |
The market report also presents an in-depth analysis of various stakeholders contributing to the aseptic fill finish manufacturing market growth, highlighting their capabilities across different geographies. Amongst other elements, the market report includes :
One of the key objectives of this market report was to estimate the current market size and future opportunities in the aseptic fill finish manufacturing market, over the forecast period. We have provided an informed estimate of the likely evolution of the aseptic fill finish manufacturing market in the short to mid-term and long term, for the forecast period. In order to provide a detailed future outlook, year-wise projections of the current and future opportunity have been further segmented on the basis of type of molecule (small molecules and biologics), type of packaging container offered (ampoules, cartridges, prefilled syringe and vials), type of drug product (antibodies, cell therapies, gene therapies, oligonucleotides, recombinant proteins, vaccines and other drug products), target therapeutic area (autoimmune disorders, oncological disorders, cardiovascular disorders, infectious diseases and other disorders), scale of operation (preclinical / clinical and commercial), company size (large, mid-sized and small) and geography, (North America, Europe, Asia Pacific, Middle East and North Africa, and Latin America). To account for uncertainties in the market growth and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.
The opinions and insights presented in this market report are backed by our understanding of key data generated from both secondary and primary research. The perceptions presented in this study were also influenced by our discussions with senior stakeholders in the industry. The report further features detailed transcripts of interviews held with the following industry and non-industry players:
All actual figures have been sourced and analyzed from publicly available forums and primary research discussions. It is important to highlight that, financial figures mentioned in this report are in USD, unless otherwise specified.
![]() |
![]() |
Contents
1. PREFACE
1.1. Chapter Overview
1.2. Key Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Contract Manufacturing
3.3. Commonly Outsourced Operations in Biopharmaceutical Industry
3.3.1. Aseptic Fill Finish Operations
3.4. Basic Guidelines for Selecting a Fill Finish Service Provider
3.5. Advantages of Outsourcing Fill Finish Operations
3.6. Risks and Challenges Associated with Outsourcing Fill Finish Operations
3.7. Concluding Remarks
4. ASEPTIC FILL FINISH SERVICE PROVIDERS LANDSCAPE
4.1. Chapter Overview
4.2. Aseptic Fill / Finish: Service Providers Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Type of Molecule(s)
4.2.5. Analysis by Type of Packaging Container(s) Offered
5. BIOLOGICS FILL FINISH SERVICE PROVIDERS LANDSCAPE
5.1. Chapter Overview
5.2. Biologics Fill Finish: Service Providers Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Location of Fill Finish Facilities
5.2.5. Analysis by Type of Packaging Container(s) Offered
5.2.6. Analysis by Type of Drug Product(s) Involved
5.2.7. Analysis by Scale of Operation
5.2.8. Analysis by Additional Drug Product-related Services Offered
5.2.9. Information on Fill Finish Capacity
6. SMALL MOLECULE FILL FINISH SERVICE PROVIDERS LANDSCAPE
6.1. Chapter Overview
6.2. Small Molecule Fill Finish: Service Providers Landscape
6.2.1. Analysis by Year of Establishment
6.2.2. Analysis by Company Size
6.2.3. Analysis by Location of Headquarters
6.2.4. Analysis by Location of Fill Finish Facilities
6.2.5. Analysis by Type of Filling Service(s) Offered
6.2.6. Analysis by Type of Finishing Service(s) Offered
6.2.7. Analysis by Type of Packaging Container(s) Offered
6.2.8. Analysis by Scale of Operation
6.2.9. Analysis by Type of Dosage Form(s) Filled
6.2.10. Analysis by Type of Process(es)
6.2.11. Information on Fill Finish Capacity
7. COMPANY PROFILES: ASEPTIC FILL / FINISH SERVICE PROVIDERS IN NORTH AMERICA
7.1. Chapter Overview
7.2. Companies Offering Aseptic Fill Finish Services for Biologics
7.2.1. AbbVie Contract Manufacturing
7.2.1.1. Company Snapshot
7.2.1.2. Financial Information
7.2.1.3. Service Portfolio
7.2.1.4. Fill Finish Services Offered
7.2.1.5. Recent Developments and Future Outlook
7.2.2. BioPharma Solutions
7.2.2.1. Company Snapshot
7.2.2.2. Financial Information
7.2.2.3. Service Portfolio
7.2.2.4. Fill Finish Services Offered
7.2.2.5. Recent Developments and Future Outlook
7.2.3. BioReliance
7.2.3.1. Company Snapshot
7.2.3.2. Financial Information
7.2.3.3. Service Portfolio
7.2.3.4. Fill Finish Services Offered
7.2.3.5. Recent Developments and Future Outlook
7.2.4. Catalent Biologics
7.2.4.1. Company Snapshot
7.2.4.2. Financial Information
7.2.4.3. Service Portfolio
7.2.4.4. Fill Finish Services Offered
7.2.4.5. Recent Developments and Future Outlook
7.2.5. Charles River Laboratories
7.2.5.1. Company Snapshot
7.2.5.2. Financial Information
7.2.5.3. Fill Finish Services Offered
7.2.5.4. Recent Developments and Future Outlook
7.2.6. Patheon
7.2.6.1. Company Snapshot
7.2.6.2. Financial Information
7.2.6.3. Service Portfolio
7.2.6.4. Fill Finish Services Offered
7.2.6.5. Recent Developments and Future Outlook
7.3. Companies Offering Aseptic Fill Finish Services for Small Molecules
7.3.1.1. Pfizer CentreOne
7.3.1.2. Company Snapshot
7.3.1.3. Service Portfolio
7.3.1.4. Fill Finish Services Offered
7.3.1.5. Recent Developments and Future Outlook
7.3.2. Plastikon Healthcare
7.3.2.1. Company Snapshot
7.3.2.2. Service Portfolio
7.3.2.3. Fill Finish Services Offered
7.3.2.4. Recent Developments and Future Outlook
7.3.3. Sharp Services
7.3.3.1. Company Snapshot
7.3.3.2. Service Portfolio
7.3.3.3. Fill Finish Services Offered
7.3.3.4. Recent Developments and Future Outlook
8. COMPANY PROFILES: ASEPTIC FILL FINISH SERVICE PROVIDERS IN EUROPE
8.1. Company Overview
8.2. Companies Offering Aseptic Fill Finish Services for Biologics
8.2.1. Boehringer Ingelheim BioXcellence
8.2.1.1. Company Snapshot
8.2.1.2. Financial Information
8.2.1.3. Service Portfolio
8.2.1.4. Fill Finish Services Offered
8.2.1.5. Recent Developments and Future Outlook
8.2.2. Fareva
8.2.2.1. Company Snapshot
8.2.2.2. Fill Finish Services Offered
8.2.2.3. Recent Developments and Future Outlook
8.2.3. GlaxoSmithKline
8.2.3.1. Company Snapshot
8.2.3.2. Financial Information
8.2.3.3. Fill Finish Services Offered
8.2.3.4. Recent Developments and Future Outlook
8.2.4. Lonza
8.2.4.1. Company Snapshot
8.2.4.2. Financial Information
8.2.4.3. Service Portfolio
8.2.4.4. Fill Finish Services Offered
8.2.4.5. Recent Developments and Future Outlook
8.2.5. Pierre Fabre
8.2.5.1. Company Snapshot
8.2.5.2. Financial Information
8.2.5.3. Service Portfolio
8.2.5.4. Fill Finish Services Offered
8.2.5.5. Recent Developments and Future Outlook
8.2.6. Wacker Biotech
8.2.6.1. Company Snapshot
8.2.6.2. Financial Information
8.2.6.3. Service Portfolio
8.2.6. 4. Fill Finish Services Offered
8.2.6.5. Recent Developments and Future Outlook
8.3. Companies Offering Aseptic Fill Finish Services for Small Molecules
8.3.1. Aenova
8.3.1.1. Company Snapshot
8.3.1.2. Financial Information
8.3.1.3. Service Portfolio
8.3.1.4. Fill Finish Services Offered
8.3.1.5. Recent Developments and Future Outlook
8.3.2. APL
8.3.2.1. Company Snapshot
8.3.2.2. Service Portfolio
8.3.2.3. Fill Finish Services Offered
8.3.2.4. Recent Developments and Future Outlook
8.3.3 CordenPharma
8.3.3.1. Company Snapshot
8.3.3.2. Service Portfolio
8.3.3.3. Fill Finish Services Offered
8.3.3.4. Recent Developments and Future Outlook
8.3.4. Delpharm
8.3.4.1. Company Snapshot
8.3.4.2. Service Portfolio
8.3.4.3. Fill Finish Services Offered
8.3.4.4. Recent Developments and Future Outlook
8.3.5 PiSA Farmaceutica
8.3.5.1. Company Snapshot
8.3.5.2. Service Portfolio
8.3.5.3. Fill Finish Services Offered
8.3.5.4. Recent Developments and Future Outlook
8.4 Companies Offering Aseptic Fill Finish Manufacturing for Biologics and Small Molecules
8.4.1 Fresenius Kabi
8.4.1.1. Company Snapshot
8.4.1.2 Financial Information
8.4.1.3. Service Portfolio
8.4.1.4. Fill Finish Services Offered
8.4.1.5. Recent Developments and Future Outlook
8.4.2 Recipharm
8.4.2.1. Company Snapshot
8.4.2.2. Financial Information
8.4.2.3. Service Portfolio
8.4.2.4. Fill Finish Services Offered
8.4.2.5. Recent Developments and Future Outlook
9. COMPANY PROFILES: ASEPTIC FILL FINISH SERVICE PROVIDERS IN ASIA-PACIFIC
9.1 Company Overview
9.2 Companies Offering Aseptic Fill Finish Services for Biologics
9.2.1 Asymchem
9.2.1.1. Company Snapshot
9.2.1.2. Financial Information
9.2.1.3. Service Portfolio
9.2.1.4. Fill Finish Services Offered
9.2.1.5. Recent Developments and Future Outlook
9.2.2. Samsung Biologics
9.2.2.1. Company Snapshot
9.2.2.2. Financial Information
9.2.2.3. Service Portfolio
9.2.2.4. Fill Finish Services Offered
9.2.2.5. Recent Developments and Future Outlook
9.2.3. Syngene
9.2.3.1. Company Snapshot
9.2.3.2. Financial Information
9.2.3.3. Service Portfolio
9.2.3.4. Fill Finish Services Offered
9.2.3.5. Recent Developments and Future Outlook
9.2.4. Takara Bio
9.2.4.1. Company Snapshot
9.2.4.2. Financial Information
9.2.4.3. Service Portfolio
9.2.4.4. Fill Finish Services Offered
9.2.4.5. Recent Developments and Future Outlook
9.2.5. WuXi Biologics
9.2.5.1. Company Snapshot
9.2.5.2. Financial Information
9.2.5.3. Service Portfolio
9.2.5.4. Fill Finish Services Offered
9.2.5.5. Recent Developments and Future Outlook
9.2.6. Hetero Drugs
9.2.6.1. Company Snapshot
9.2.6.2. Fill Finish Services Offered
9.2.6.3. Recent Developments and Future Outlook
9.2.7. Intas Pharmaceuticals
9.2.7.1. Company Snapshot
9.2.7.2. Fill Finish Services Offered
9.2.7.3. Recent Developments and Future Outlook
9.3. Companies Offering Aseptic Fill Finish Services for Small Molecules
9.3.1. Siegfried
9.3.1.1. Company Snapshot
9.3.1.2. Financial Information
9.3.1.3. Service Portfolio
9.3.1.4. Fill Finish Services Offered
9.3.1.5. Recent Developments and Future Outlook
9.3.2. Wockhardt
9.3.2.1. Company Snapshot
9.3.2.2. Financial Information
9.3.2.3. Service Portfolio
9.3.2.4. Fill Finish Services Offered
9.3.2.5. Recent Developments and Future Outlook
10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Aseptic Fill Finish Service Providers: List of Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Scale of Operation
10.3.4. Analysis by Type of Molecule(s) Involved
10.3.5. Analysis by Type of Service(s) Offered
10.3.6. Analysis by Type of Process(es) Involved
10.3.7. Analysis by Type of Drug Product(s) Involved
10.3.8. Most Active Players: Analysis by Number of Partnerships
10.3.9. Analysis by Geography
10.3.9.1. Intercontinental and Intracontinental Agreements
11. MARKET SIZING AND OPPORTUNITY ANALYSIS
11.1. Chapter Overview
11.2. Forecast Methodology
11.3. Overall Aseptic Fill Finish Manufacturing Market, 2023-2035
11.3.1. Aseptic Fill Finish Services Market: Analysis by Type of Molecule, 2023-2035
11.3.2. Aseptic Fill Finish Manufacturing Market: Analysis by Type of Packaging Container Offered, 2023-2035
11.3.3. Aseptic Fill Finish Manufacturing Market: Analysis by Type of Drug Product, 2023-2035
11.3.4. Aseptic Fill Finish Manufacturing Market: Analysis by Target Therapeutic Area, 2023-2035
11.3.5. Aseptic Fill Finish Manufacturing Market: Analysis by Scale of Operation, 2023-2035
11.3.6. Aseptic Fill Finish Manufacturing Market: Analysis by Company Size, 2023-2035
11.3.7. Aseptic Fill Finish Manufacturing Market: Analysis by Geography, 2023-2035
11.4. Aseptic Fill Finish Manufacturing Market for Biologics, 2023-2035
11.4.1. Aseptic Fill Finish Manufacturing Market for Biologics: Analysis by Type of Packaging Container Offered, 2023-2035
11.4.2. Aseptic Fill Finish Manufacturing Market: Analysis by Type of Drug Product, 2023-2035
11.4.3. Aseptic Fill Finish Manufacturing Market for Biologics: Analysis by Target Therapeutic Area, 2023-2035
11.4.4. Aseptic Fill Finish Manufacturing Market for Biologics: Analysis by Scale of Operation, 2023-2035
11.4.5. Aseptic Fill Finish Manufacturing Market for Biologics: Analysis by Company Size, 2023-2035
11.4.6. Aseptic Fill Finish Manufacturing Market for Biologics: Analysis by Geography, 2023-2035
11.5. Aseptic Fill Finish Manufacturing Market for Small Molecules, 2023-2035
11.5.1. Aseptic Fill Finish Manufacturing Market for Small Molecules: Analysis by Type of Packaging Container Offered, 2023-2035
11.5.2. Aseptic Fill Finish Manufacturing Market for Small Molecules: Analysis by Scale of Operation, 2023-2035
11.5.3. Aseptic Fill Finish Manufacturing Market for Small Molecules: Analysis by Company Size, 2023-2035
11.5.4. Aseptic Fill Finish Manufacturing Market for Small Molecules: Analysis by Geography, 2023-2035
12. CASE STUDY: ROBOTICS IN PHARMACEUTICAL PACKAGING
12.1. Chapter Overview
12.2. Role of Robotic Systems in Pharmaceutical Industry
12.3. Role of Robotic Systems in Fill / Finish Operation
12.3.1. Types of Robots Used in Pharmaceutical Operations
12.3.2. Advantages Associated with Robotic Systems
12.3.3. Disadvantages Associated with Robotic Systems
12.4.2. Key Considerations for Selecting a Robotic System
12.3. Contract Service Providers: List of Fill Finish Equipment
12.5. Companies Providing Robots for Use in the Pharmaceutical Industry
12.6. Companies Providing Isolator based Aseptic Filling Systems
12.7. Concluding Remarks
13. CASE STUDY: READY-TO-USE PACKAGING COMPONENTS FOR ASEPTIC FILL FINISH
13.1. Chapter Overview
13.2. Role of Ready-to-Use Packaging Components in Aseptic Fill Finish Operations
13.2.1. Advantages of Ready to Use Packaging Components
13.2.2. Disadvantages of Ready to Use Packaging Components
13.3. Companies Providing Ready to Use Packaging Components
13.4. Concluding Remarks
14. CONCLUDING REMARKS
15. EXECUTIVE INSIGHTS
15.1 Chapter Overview
15.2 IDT Biologika
15.2.1. Company Snapshot
15.2.1. Interview Transcript: Gregor Kawaletz, Former Chief Commercial Officer
15.3 Cytovance Biologics
15.3.1. Company Snapshot
15.3.2. Interview Transcript: Matt Delaney, Former Vice President of Business Development and Marketing
15.4. Syngene
15.4.1. Company Snapshot
15.4.2. Interview Transcript: Purushottam Singnurkar, Vice President and Head of Formulation Development
15.5 oncomed manufacturing
15.5.1. Company Snapshot
15.5.2. Interview Transcript: Ales Sima, Head of Business Development
15.6 Yposkesi
15.6.1. Company Snapshot
15.6.2. Interview Transcript: Amit, Former Technology Watch Manager
15.7 HALIX
15.7.1. Company Snapshot
15.7.2. Interview Transcript: Jos Vergeest, International Business Developer
16. APPENDIX 1: TABULATED DATA
17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 2.1 Executive Summary: Market Landscape of Biologics Fill Finish Service Providers
Figure 2.2 Executive Summary: Market Landscape of Small Molecules Fill Finish Service Providers
Figure 2.3 Executive Summary: Partnerships and Collaborations
Figure 2.4 Executive Summary: Market Forecast and Opportunity Analysis
Figure 3.1 Types of Third-Party Service Providers
Figure 3.2 Commonly Outsourced Fill Finish Operations
Figure 3.3 Steps Involved in Aseptic Fill Finish Process
Figure 3.4 Blow-Fill-Seal Process
Figure 3.5 Key Considerations for Selecting a CMO Partner
Figure 3.6 Risks and Challenges Associated with Outsourcing Aseptic Fill Finish Operations
Figure 4.1 Aseptic Fill Finish Service Providers: Distribution by Year of Establishment
Figure 4.2 Aseptic Fill Finish Service Providers: Distribution by Company Size
Figure 4.3 Aseptic Fill Finish Service Providers: Distribution by Location of Headquarters
Figure 4.4 Aseptic Fill Finish Service Providers: Distribution by Type of Molecule(s)
Figure 4.5 Aseptic Fill Finish Service Providers: Distribution by Type of Packaging Container(s) Offered
Figure 5.1 Biologics Fill Finish Service Providers: Distribution by Year of Establishment
Figure 5.2 Biologics Fill Finish Service Providers: Distribution by Company Size
Figure 5.3 Biologics Fill Finish Service Providers: Distribution by Location of Headquarters
Figure 5.4 Biologics Fill Finish Service Providers: Distribution by Location of Fill Finish Facilities
Figure 5.5 Biologics Fill Finish Service Providers: Distribution by Type of Packaging Container(s) Offered
Figure 5.6 Biologics Fill Finish Service Providers: Distribution by Type of Packaging Container(s) Offered and Type of Drug Product(s) Involved
Figure 5.7 Biologics Fill Finish Service Providers: Distribution by Scale of Operation
Figure 5.8 Biologics Fill Finish Service Providers: Distribution by Additional Drug Product-related Services Offered
Figure 6.1 Small Molecules Fill Finish Service Providers: Distribution by Year of Establishment
Figure 6.2 Small Molecules Fill Finish Service Providers: Distribution by Company Size
Figure 6.3 Small Molecules Fill Finish Service Providers: Distribution by Location of Headquarters
Figure 6.4 Small Molecules Fill Finish Service Providers: Distribution by Location of Fill / Finish Facilities
Figure 6.5 Small Molecules Fill Finish Service Providers: Distribution by Type of Filling Service(s) Offered
Figure 6.6 Small Molecules Fill Finish Service Providers: Distribution by Type of Finishing Service(s) Offered
Figure 6.7 Small Molecules Fill Finish Service Providers: Distribution by Type of Packaging Container(s) Offered
Figure 6.8 Small Molecules Fill Finish Service Providers: Distribution by Scale of Operation
Figure 6.9 Small Molecules Fill Finish Service Providers: Distribution by Type of Dosage Form(s) Filled
Figure 6.10 Small Molecules Fill Finish Service Providers: Distribution by Type of Process(es)
Figure 7.1 AbbVie: Annual Revenues, 2017-H1 2022 (USD Billion)
Figure 7.2 Baxter (a parent company of BioPharma Solutions): Annual Revenues, 2017-H1 2022 (USD Billion)
Figure 7.3 Merck (a parent company of BioReliance): Annual Revenues, 2017-H1 2022 (EUR Billion)
Figure 7.4 Catalent Biologics: Annual Revenues, FY 2017-FY 2022 (USD Billion)
Figure 7.5 Charles River Laboratories: Annual Revenues, 2017-H1 2022 (USD Billion)
Figure 7.6 Thermo Fisher Scientific (a parent company of Patheon): Annual Revenues, 2017-H1 2022 (USD Billion)
Figure 7.7 Pfizer CentreOne: Annual Revenues, 2017-9M 2022 (USD Million)
Figure 8.1 Boehringer Ingelheim (a parent company of Boehringer Ingelheim BioXcellence): Annual Revenues, 2017-H1 2022 (EUR Billion)
Figure 8.2 GlaxoSmithKline: Annual Revenues, 2017 –H1 2022 (GBP Billion)
Figure 8.3 Lonza: Annual Revenues, 2017-H1 2022 (CHF Billion)
Figure 8.4 Pierre Fabre: Annual Revenues, 2018- 2021 (EUR Billion)
Figure 8.5 Wacker Chemie ( a parent company of Wacker Biotech): Annual Revenues, 2017-H1 2022 (EUR Billion)
Figure 8.6 Aenova: Annual Revenues, 2018-2021 (EUR Million)
Figure 8.7 Fresenius Kabi: Annual Revenues, 2017-9M 2022 (EUR Billion)
Figure 8.8 Recipharm: Annual Revenues, 2017- 2020 (SEK Billion)
Figure 8.9 Recipharm: Revenues by Business Divisions, 2020 (SEK Billion)
Figure 9.1 Asymchem: Annual Revenues, 2017-2020 (USD Billion)
Figure 9.2 Samsung Biologics: Annual Revenues, 2017-H1 2022 (KRW Billion)
Figure 9.3 Syngene: Annual Revenues, FY 2017-FY 2022 (INR Million)
Figure 9.4 Takara Bio: Annual Revenues, FY 2017-FY 2022 (JPY Billion)
Figure 9.5 WuXi Biologics: Annual Revenues, 2017-H1 2022 (RMB Million)
Figure 9.6 Siegfried: Annual Revenues, 2017-H1 2022 (CHF Million)
Figure 9.7 Wockhardt: Annual Revenues, FY 2017- FY Q1 2023 (INR Billion)
Figure 10.1 Partnerships and Collaborations: Cumulative Year wise Trend, 2013-2022
Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3 Partnerships and Collaborations: Distribution by Scale of Operation
Figure 10.4 Partnerships and Collaborations: Distribution by Type of Molecule(s) Involved
Figure 10.5 Partnerships and Collaborations: Distribution by Type of Service(s) Offered
Figure 10.6 Partnerships and Collaborations: Distribution by Type of Process(es) Involved
Figure 10.7 Partnerships and Collaborations: Distribution by Type of Drug Product(s) Involved
Figure 10.8 Most Active Players: Distribution by Number of Partnerships
Figure 10.9 Partnerships and Collaborations: Distribution by Geography
Figure 10.10 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 11.1 Global Aseptic Fill Finish Manufacturing Market, 2023-2035 (USD Billion)
Figure 11.2 Aseptic Fill Finish Manufacturing Market: Distribution by Type of Molecule, 2023-2035 (USD Billion)
Figure 11.3 Aseptic Fill Finish Manufacturing Market: Distribution by Type of Packaging Container Offered, 2023-2035 (USD Billion)
Figure 11.4 Aseptic Fill Finish Manufacturing Market: Distribution by Type of Drug Product, 2023-2035 (USD Billion)
Figure 11.5 Aseptic Fill Finish Manufacturing Market: Distribution by Target Therapeutic Area, 2023-2035 (USD Billion)
Figure 11.6 Aseptic Fill Finish Manufacturing Market: Distribution by Scale of Operation, 2023-2035 (USD Billion)
Figure 11.7 Aseptic Fill Finish Manufacturing Market: Distribution by Company Size, 2023-2035 (USD Billion)
Figure 11.8 Aseptic Fill Finish Manufacturing Market: Distribution by Geography, 2023-2035 (USD Billion)
Figure 11.9 Aseptic Fill Finish Manufacturing Market for Biologics, 2023-2035 (USD Billion)
Figure 11.10 Aseptic Fill Finish Manufacturing Market for Biologics: Distribution by Type of Packaging Container Offered, 2023-2035 (USD Billion)
Figure 11.11 Aseptic Fill Finish Manufacturing Market for Biologics: Distribution by Type of Drug Product, 2023-2035 (USD Billion)
Figure 11.12 Aseptic Fill Finish Manufacturing Market for Biologics: Distribution by Target Therapeutic Area, 2023-2035 (USD Billion)
Figure 11.13 Aseptic Fill Finish Manufacturing Market for Biologics: Distribution by Scale of Operation, 2023-2035 (USD Billion)
Figure 11.14 Aseptic Fill Finish Manufacturing Market for Biologics: Distribution by Company Size, 2023-2035 (USD Billion)
Figure 11.15 Aseptic Fill Finish Manufacturing Market for Biologics: Distribution by Geography, 2023-2035 (USD Billion)
Figure 11.16 Aseptic Fill Finish Manufacturing Market for Small Molecules, 2023-2035 (USD Billion)
Figure 11.17 Aseptic Fill Finish Manufacturing Market for Small Molecules: Distribution by Type of Packaging Container Offered, 2023-2035 (USD Billion)
Figure 11.18 Aseptic Fill Finish Manufacturing Market for Small Molecules: Distribution by Scale of Operation, 2023-2035 (USD Billion)
Figure 11.19 Aseptic Fill Finish Manufacturing Market for Small Molecules: Distribution by Company Size, 2023-2035 (USD Billion)
Figure 11.20 Aseptic Fill Finish Manufacturing Market for Small Molecules: Distribution by Geography, 2023-2035 (USD Billion)
Figure 12.1 Key Considerations for Selecting a Robotic System
Figure 12.2 Advantages of Robotic Systems in Pharmaceutical Operations
Figure 13.1 Key Drivers of Ready-to-Use Platform
Figure 14.1 Concluding Remarks: Current Biologic Fill Finish Service Providers Market Landscape
Figure 14.2 Concluding Remarks: Current Small Molecule Fill / Finish Service Providers Market Landscape
Figure 14.3 Concluding Remarks: Partnerships and Collaborations
Figure 14.4 Concluding Remarks: Market Sizing and Opportunity Analysis
Table 4.1 Aseptic Fill Finish Service Providers: List of Companies
Table 4.2 Aseptic Fill Finish Service Providers: Information on Type of Packaging Container(s) Offered
Table 5.1 Biologics Fill Finish Service Providers: List of Companies
Table 5.2 Biologics Fill Finish Service Providers: Information on Type of Packaging Container(s) Offered
Table 5.3 Biologics Fill Finish Service Providers: Information on Type of Drug Product(s) Involved
Table 5.4 Biologics Fill Finish Service Providers: Information on Scale of Operation
Table 5.5 Biologics Fill Finish Service Providers: Information on Additional Drug Product-related Services Offered
Table 5.6 Biologics Fill Finish Service Providers: Information on Fill Finish Capacity
Table 6.1 Small Molecules Fill Finish Service Providers: List of Companies
Table 6.2 Small Molecules Fill Finish Service Providers: Information on Fill Finish Technique
Table 6.3 Small Molecules Fill Finish Service Providers: Information on Type of Packaging Container(s) Offered
Table 6.4 Small Molecules Fill Finish Service Providers: Information on Scale of Operation
Table 6.5 Small Molecules Fill Finish Service Providers: Information on Type of Dosage Form(s) Filled and Type of Process(es)
Table 6.6 Small Molecules Fill Finish Service Providers: Information on Fill Finish Capacity
Table 7.1 Biologics Fill Finish Service Providers: List of Companies Profiled
Table 7.2 AbbVie Contract Manufacturing: Company Snapshot
Table 7.3 AbbVie Contract Manufacturing: Service Portfolio
Table 7.4 AbbVie Contract Manufacturing: Fill Finish Manufacturing
Table 7.5 AbbVie Contract Manufacturing: Sterile Manufacturing Facilities
Table 7.6 AbbVie Contract Manufacturing: Recent Developments and Future Outlook
Table 7.7 BioPharma Solutions: Company Snapshot
Table 7.8 BioPharma Solutions: Service Portfolio
Table 7.9 BioPharma Solutions: Fill Finish Manufacturing
Table 7.10 BioPharma Solutions: Sterile Manufacturing Facilities
Table 7.11 BioPharma Solutions: Recent Developments and Future Outlook
Table 7.12 BioReliance: Company Snapshot
Table 7.13 BioReliance: Service Portfolio
Table 7.14 BioReliance: Fill Finish Manufacturing
Table 7.15 BioReliance: Sterile Manufacturing Facilities
Table 7.16 BioReliance: Recent Developments and Future Outlook
Table 7.17 Catalent Biologics: Company Snapshot
Table 7.18 Catalent Biologics: Service Portfolio
Table 7.19 Catalent Biologics: Fill Finish Manufacturing
Table 7.20 Catalent Biologics: Sterile Manufacturing Facilities
Table 7.21 Catalent Biologics: Recent Developments and Future Outlook
Table 7.22 Charles River Laboratories: Company Snapshot
Table 7.23 Charles River Laboratories: Fill Finish Manufacturing
Table 7.24 Charles River Laboratories: Sterile Manufacturing Facilities
Table 7.25 Charles River Laboratories: Recent Developments and Future Outlook
Table 7.26 Patheon: Company Snapshot
Table 7.27 Patheon: Service Portfolio
Table 7.28 Patheon: Fill Finish Manufacturing
Table 7.29 Patheon: Recent Developments and Future Outlook
Table 7.30 Small Molecules Fill Finish Service Providers: List of Companies Profiled
Table 7.31 Pfizer CentreOne: Company Snapshot
Table 7.32 Pfizer CentreOne: Service Portfolio
Table 7.33 Pfizer CentreOne: Fill Finish Manufacturing
Table 7.34 Pfizer CentreOne: Recent Developments and Future Outlook
Table 7.35 Plastikon Healthcare: Company Snapshot
Table 7.36 Plastikon Healthcare: Service Portfolio
Table 7.37 Plastikon Healthcare: Fill Finish Manufacturing
Table 7.38 Sharp Services: Company Snapshot
Table 7.39 Sharp Services: Service Portfolio
Table 7.40 Sharp Services: Fill Finish Manufacturing
Table 7.41 Sharp Services: Recent Developments and Future Outlook
Table 8.1 Biologics Fill / Finish Service Providers in Europe: List of Companies Profiled
Table 8.2 Boehringer Ingelheim BioXcellence: Company Snapshot
Table 8.3 Boehringer Ingelheim BioXcellence: Service Portfolio
Table 8.4 Boehringer Ingelheim BioXcellence: Fill Finish Manufacturing
Table 8.5 Boehringer Ingelheim BioXcellence: Sterile Manufacturing Facilities
Table 8.6 Boehringer Ingelheim BioXcellence: Recent Developments and Future Outlook
Table 8.7 Fareva: Company Snapshot
Table 8.8 Fareva: Fill Finish Manufacturing
Table 8.9 Fareva: Recent Developments and Future Outlook
Table 8.10 Glaxo SmithKline: Company Snapshot
Table 8.11 Glaxo SmithKline: Fill Finish Manufacturing
Table 8.12 Glaxo SmithKline: Recent Developments and Future Outlook
Table 8.13 Lonza: Company Snapshot
Table 8.14 Lonza: Service Portfolio
Table 8.15 Lonza: Fill Finish Manufacturing
Table 8.16 Lonza: Recent Developments and Future Outlook
Table 8.17 Pierre Fabre: Company Snapshot
Table 8.18 Pierre Fabre: Service Portfolio
Table 8.19 Pierre Fabre: Fill Finish Manufacturing
Table 8.20 Pierre Fabre: Sterile Manufacturing Facilities
Table 8.21 Pierre Fabre: Recent Developments and Future Outlook
Table 8.22 Wacker Biotech: Company Snapshot
Table 8.23 Wacker Biotech: Service Portfolio
Table 8.24 Wacker Biotech: Fill Finish Manufacturing
Table 8.25 Wacker Biotech: Sterile Manufacturing Facilities
Table 8.26 Wacker Biotech: Recent Developments and Future Outlook
Table 8.27 Small Molecules Fill Finish Service Providers in Europe: List of Companies Profiled
Table 8.28 Aenova: Company Snapshot
Table 8.29 Aenova: Service Portfolio
Table 8.30 Aenova: Fill Finish Manufacturing
Table 8.31 Aenova: Recent Developments and Future Outlook
Table 8.32 APL: Company Snapshot
Table 8.33 APL: Service Portfolio
Table 8.34 APL: Fill Finish Manufacturing
Table 8.35 CordenPharma: Company Snapshot
Table 8.36 CordenPharma: Service Portfolio
Table 8.37 CordenPharma: Fill Finish Manufacturing
Table 8.38 CordenPharma: Recent Developments and Future Outlook
Table 8.39 Delpharm: Company Snapshot
Table 8.40 Delpharm: Service Portfolio
Table 8.41 Delpharm: Fill Finish Manufacturing
Table 8.42 Delpharm: Recent Developments and Future Outlook
Table 8.43 PiSA Farmaceutica: Company Snapshot
Table 8.44 PiSA Farmaceutica: Fill Finish Manufacturing
Table 8.45 Biologics and Small Molecules Fill Finish Service Providers in Europe: List of Companies Profiled
Table 8.46 Fresenius Kabi: Company Snapshot
Table 8.47 Fresenius Kabi: Fill Finish Manufacturing
Table 8.48 Recipharm: Company Snapshot
Table 8.49 Recipharm: Service Portfolio
Table 8.50 Recipharm: Fill Finish Manufacturing
Table 8.51 Recipharm: Recent Developments and Future Outlook
Table 9.1 Biologics Fill Finish Service Providers in Asia-Pacific: List of Companies Profiled
Table 9.2 Asymchem: Company Snapshot
Table 9.3 Asymchem: Service Portfolio
Table 9.4 Asymchem: Fill Finish Manufacturing
Table 9.5 Asymchem: Sterile Manufacturing Facilities
Table 9.6 Asymchem: Recent Developments and Future Outlook
Table 9.7 Samsung Biologics: Company Snapshot
Table 9.8 Samsung Biologics: Service Portfolio
Table 9.9 Samsung Biologics: Fill Finish Manufacturing
Table 9.10 Samsung Biologics: Recent Developments and Future Outlook
Table 9.11 Syngene: Company Snapshot
Table 9.12 Syngene: Service Portfolio
Table 9.13 Syngene: Fill Finish Manufacturing
Table 9.14 Syngene: Recent Developments and Future Outlook
Table 9.15 Takara Bio: Company Snapshot
Table 9.16 Takara Bio: Service Portfolio
Table 9.17 Takara Bio: Fill Finish Manufacturing
Table 9.18 Takara Bio: Recent Developments and Future Outlook
Table 9.19 WuXi Biologics: Company Snapshot
Table 9.20 WuXi Biologics: Services Portfolio
Table 9.21 Wuxi Biologics: Fill Finish Manufacturing
Table 9.22 WuXi Biologics: Sterile Manufacturing Facilities
Table 9.23 WuXi Biologics: Recent Developments and Future Outlook
Table 9.24 Hetero Drugs: Company Snapshot
Table 9.25 Hetero Drugs: Fill Finish Manufacturing
Table 9.26 Intas Pharmaceuticals: Company Snapshot
Table 9.27 Intas Pharmaceuticals: Fill Finish Manufacturing
Table 9.28 Small Molecules Fill / Finish Service Providers in Asia-Pacific: List of Companies Profiled
Table 9.29 Siegfried: Company Snapshot
Table 9.30 Siegfried: Service Portfolio
Table 9.31 Siegfried: Fill Finish Manufacturing
Table 9.32 Siegfried: Recent Developments and Future Outlook
Table 9.33 Wockhardt: Company Snapshot
Table 9.34 Wockhardt: Fill Finish Manufacturing
Table 9.35 Wockhardt: Recent Developments and Future Outlook
Table 10.1 Aseptic Fill Finish Service Providers: Partnerships and Collaborations
Table 10.2 Partnerships and Collaborations: Information on Type of Molecule(s) Involved and Type of Service(s) Offered
Table 10.3 Partnerships and Collaborations: Information on Type of Drug Product(s) Involved and Type of Process(es) Involved
Table 12.1 Contract Service Providers: Information on Fill Finish Equipment
Table 12.2 List of Pharmaceutical Robotics Manufacturers
Table 12.3 Isolator based Aseptic Filling Systems: Information on Compatible Primary Container
Table 13.1 List of Companies Supplying Ready-to-Use Aseptic Packaging Components
Table 16.1 Aseptic Fill Finish Service Providers: Distribution by Year of Establishment
Table 16.2 Aseptic Fill Finish Service Providers: Distribution by Company Size
Table 16.3 Aseptic Fill Finish Service Providers: Distribution by Location of Headquarters
Table 16.4 Aseptic Fill Finish Service Providers: Distribution by Type of Molecule(s)
Table 16.5 Aseptic Fill Finish Service Providers: Distribution by Type of Packaging Container(s) Offered
Table 16.6 Biologics Fill Finish Service Providers: Distribution by Year of Establishment
Table 16.7 Biologics Fill Finish Service Providers: Distribution by Company Size
Table 16.8 Biologics Fill Finish Service Providers: Distribution by Location of Headquarters
Table 16.9 Biologics Fill Finish Service Providers: Distribution by Location of Fill Finish Facilities
Table 16.10 Biologics Fill Finish Service Providers: Distribution by Type of Packaging Container(s) Offered
Table 16.11 Biologics Fill Finish Service Providers: Distribution by Type of Packaging Container(s) Offered and Type of Drug Product(s) Involved
Table 16.12 Biologics Fill Finish Service Providers: Distribution by Scale of Operation
Table 16.13 Biologics Fill Finish Service Providers: Distribution by Additional Drug Product-related Services Offered
Table 16.14 Small Molecules Fill Finish Service Providers: Distribution by Year of Establishment
Table 16.15 Small Molecules Fill Finish Service Providers: Distribution by Company Size
Table 16.16 Small Molecules Fill Finish Service Providers: Distribution by Location of Headquarters
Table 16.17 Small Molecules Fill Finish Service Providers: Distribution by Location of Fill Finish Facilities
Table 16.18 Small Molecules Fill Finish Service Providers: Distribution by Type of Filling Service(s) Offered
Table 16.19 Small Molecules Fill Finish Service Providers: Distribution by Type of Finishing Service(s) Offered
Table 16.19 Small Molecules Fill Finish Service Providers: Distribution by Type of Packaging Container(s) Offered
Table 16.20 Small Molecules Fill Finish Service Providers: Distribution by Scale of Operation
Table 16.21 Small Molecules Fill Finish Service Providers: Distribution by Type of Dosage Form(s) Filled
Table 16.22 Small Molecules Fill Finish Service Providers: Distribution by Type of Process(es)
Table 16.23 AbbVie: Annual Revenues, 2017-H1 2022 (USD Billion)
Table 16.24 Baxter (a parent company of BioPharma Solutions): Annual Revenues, 2017-H1 2022 (USD Billion)
Table 16.25 Merck (a parent company of BioReliance): Annual Revenues, 2017-H1 2022 (EUR Billion)
Table 16.26 Catalent Biologics: Annual Revenues, FY 2017-FY 2022 (USD Billion)
Table 16.27 Charles River Laboratories: Annual Revenues, 2017-H1 2022 (USD Billion)
Table 16.28 Thermo Fisher Scientific (a parent company of Patheon): Annual Revenues, 2017-H1 2022 (USD Billion)
Table 16.29 Pfizer CentreOne: Annual Revenues, 2017-9M 2022 (USD Million)
Table 16.30 Boehringer Ingelheim (a parent company of Boehringer Ingelheim BioXcellence): Annual Revenues, 2017-H1 2022 (EUR Billion)
Table 16.31 GlaxoSmithKline: Annual Revenues, 2017 –H1 2022 (GBP Billion)
Table 16.32 Lonza: Annual Revenues, 2017-H1 2022 (CHF Billion)
Table 16.33 Pierre Fabre: Annual Revenues, 2018- 2021 (EUR Billion)
Table 16.34 Wacker Chemie ( a parent company of Wacker Biotech): Annual Revenues, 2017-H1 2022 (EUR Billion)
Table 16.35 Aenova: Annual Revenues, 2018-2021 (EUR Million)
Table 16.36 Fresenius Kabi: Annual Revenues, 2017-9M 2022 (EUR Billion)
Table 16.37 Recipharm: Annual Revenues, 2017- 2020 (SEK Billion)
Table 16.38 Recipharm: Revenues by Business Divisions, 2020 (SEK Billion)
Table 16.39 Asymchem: Annual Revenues, 2017-2020 (USD Billion)
Table 16.40 Samsung Biologics: Annual Revenues, 2017-H1 2022 (KRW Billion)
Table 16.41 Syngene: Annual Revenues, FY 2017-FY 2022 (INR Million)
Table 16.42 Takara Bio: Annual Revenues, FY 2017-FY 2022 (JPY Billion)
Table 16.43 WuXi Biologics: Annual Revenues, 2017-H1 2022 (RMB Million)
Table 16.44 Siegfried: Annual Revenues, 2017-H1 2022 (CHF Million)
Table 16.45 Wockhardt: Annual Revenues, FY 2017- FY Q1 2023 (INR Billion)
Table 16.46 Partnerships and Collaborations: Cumulative Year wise Trend, 2013-2022
Table 16.47 Partnerships and Collaborations: Distribution by Type of Partnership
Table 16.48 Partnerships and Collaborations: Distribution by Scale of Operation
Table 16.49 Partnerships and Collaborations: Distribution by Type of Molecule(s) Involved
Table 16.50 Partnerships and Collaborations: Distribution by Type of Service(s) Offered
Table 16.51 Partnerships and Collaborations: Distribution by Type of Process(es) Involved
Table 16.52 Partnerships and Collaborations: Distribution by Type of Drug Product(s) Involved
Table 16.53 Most Active Players: Distribution by Number of Partnerships
Table 16.54 Partnerships and Collaborations: Distribution by Geography
Table 16.55 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 16.56 Global Aseptic Fill Finish Manufacturing Market, 2023-2035 (USD Billion)
Table 16.57 Aseptic Fill Finish Manufacturing Market, Conservative, Base and Optimistic Scenarios: Distribution by Type of Molecule, 2023-2035 (USD Billion)
Table 16.58 Aseptic Fill Finish Manufacturing Market, Conservative, Base and Optimistic Scenarios: Distribution by Type of Packaging Container Offered, 2023-2035 (USD Billion)
Table 16.59 Aseptic Fill Finish Manufacturing Market, Conservative, Base and Optimistic Scenarios: Distribution by Type of Drug Product, 2023-2035 (USD Billion)
Table 16.60 Aseptic Fill Finish Manufacturing Market, Conservative, Base and Optimistic Scenarios: Distribution by Target Therapeutic Area, 2023-2035 (USD Billion)
Table 16.61 Aseptic Fill Finish Manufacturing Market, Conservative, Base and Optimistic Scenarios: Distribution by Scale of Operation, 2023-2035 (USD Billion)
Table 16.62 Aseptic Fill Finish Manufacturing Market, Conservative, Base and Optimistic Scenarios: Distribution by Company Size, 2023-2035 (USD Billion)
Table 16.63 Aseptic Fill Finish Manufacturing Market, Conservative, Base and Optimistic Scenarios: Distribution by Geography, 2023-2035 (USD Billion)
Table 16.64 Aseptic Fill Finish Manufacturing Market for Biologics, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 16.65 Aseptic Fill Finish Manufacturing Market for Biologics, Conservative, Base and Optimistic Scenarios: Distribution by Type of Packaging Container Offered, 2023-2035 (USD Billion)
Table 16.66 Aseptic Fill Finish Manufacturing Market for Biologics, Conservative, Base and Optimistic Scenarios: Distribution by Type of Drug Product, 2023-2035 (USD Billion)
Table 16.67 Aseptic Fill Finish Manufacturing Market for Biologics, Conservative, Base and Optimistic Scenarios: Distribution by Target Therapeutic Area, 2023-2035 (USD Billion)
Table 16.68 Aseptic Fill Finish Manufacturing Market for Biologics, Conservative, Base and Optimistic Scenarios: Distribution by Scale of Operation, 2023-2035 (USD Billion)
Table 16.69 Aseptic Fill Finish Manufacturing Market for Biologics, Conservative, Base and Optimistic Scenarios: Distribution by Company Size, 2023-2035 (USD Billion)
Table 16.70 Aseptic Fill Finish Manufacturing Market for Biologics, Conservative, Base and Optimistic Scenarios: Distribution by Geography, 2023-2035 (USD Billion)
Table 16.71 Aseptic Fill Finish Manufacturing Market for Small Molecules, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 16.72 Aseptic Fill Finish Manufacturing Market for Small Molecules, Conservative, Base and Optimistic Scenarios: Distribution by Type of Packaging Container Offered, 2023-2035 (USD Billion)
Table 16.73 Aseptic Fill Finish Manufacturing Market for Small Molecules, Conservative, Base and Optimistic Scenarios: Distribution by Scale of Operation, 2023-2035 (USD Billion)
Table 16.74 Aseptic Fill Finish Manufacturing Market for Small Molecules, Conservative, Base and Optimistic Scenarios: Distribution by Company Size, 2023-2035 (USD Billion)
Table 16.75 Aseptic Fill Finish Manufacturing Market for Small Molecules, Conservative, Base and Optimistic Scenarios: Distribution by Geography, 2023-2035 (USD Billion)
The following companies and organizations have been mentioned in the report:
Source 1: https://biologics.catalent.com/expert-content/drug-substance-manufacturing/trends-in-biologics-manufacturing-from-drug-substance-to-fill-finish/
Source 2: https://www.pharmtech.com/view/fillfinish-outsourcing